[VoiceOps] Phase III clinical trials of Kamailio DMQ

Thu Apr 1 21:11:18 EDT 2021

ROFL

Anyone paying attention to measured in kilograms ?

Happy April ! “Fools”

-- 
 J. Hellenthal

The fact that there's a highway to Hell but only a stairway to Heaven says a lot about anticipated traffic volume.

> On Apr 1, 2021, at 14:42, Carlos Alvarez <caalvarez at gmail.com> wrote:
> 
> 
> Right?  Where do they find all these blind doctors?
> 
> 
>> On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <marylou at backuptelecom.com> wrote:
>> Maybe they should open their eyes instead of doing a double-blind study! 
>> LOL!
>> 
>> MARY LOU CAREY
>> BackUP Telecom Consulting
>> Office: 615-791-9969
>> Cell: 615-796-1111
>> 
>> On 2021-04-01 02:27 PM, Hiers, David wrote:
>> > No AI here...  This is classic, small-batch, hand-crafted, free-range,
>> > organic, gluten-free content.
>> > 
>> > 
>> > David
>> > 
>> > 
>> > -----Original Message-----
>> > From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex 
>> > Balashov
>> > Sent: Thursday, April 1, 2021 12:18 PM
>> > To: Brandon Svec <bsvec at teamonesolutions.com>
>> > Cc: voiceops at voiceops.org
>> > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
>> > 
>> > Let me make sure I understand your question correctly: it is your
>> > belief or conjecture that this press release was automatically
>> > generated by a machine learning system?
>> > 
>> > —
>> > Sent from mobile, with due apologies for brevity and errors.
>> > 
>> >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> 
>> >> wrote:
>> >> 
>> >> GPT-3? Happy April Fools Day.
>> >> 
>> >> Brandon
>> >> 
>> >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov 
>> >>> <abalashov at evaristesys.com> wrote:
>> >>> 
>> >>> For immediate release:
>> >>> 
>> >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
>> >>> with Posner | Palner Pharmaceuticals, are pleased to announce the
>> >>> eagerly anticipated start of Phase III clinical trials of Kamailio
>> >>> DMQ module replication.
>> >>> 
>> >>> In this stage of the investigation of the promising replication
>> >>> scheme, which was developed in record time, DMQ will be tested in a
>> >>> rigourous, double-blind, controlled CI/CD process for large-scale
>> >>> efficacy and continually monitored for safety in shorter and longer 
>> >>> terms.
>> >>> 
>> >>> The now-concluded second phase established basic safety and Phase 2b
>> >>> entailed a dose-finding study for the optimal number of batched
>> >>> `dmq_usrloc` contacts per kilogram of cloud computing resource.
>> >>> 
>> >>> The main cohort of the main sequence of the Phase III trial will
>> >>> enroll 380 randomly selected, statistically representative Floridian
>> >>> SIP registrars and
>> >>> 5700 SIP dialogs, also in the state of Florida. When asked about the
>> >>> disparity in the number of registrars versus dialogs, Alex Balashov
>> >>> of Evariste said, "It is reflective of the small number of SIP
>> >>> registrars in Florida; not to be indelicate, but consider the median 
>> >>> age of the population."
>> >>> 
>> >>> As previously remarked upon in proceedings of the World SIP
>> >>> Organisation (WSO), the choice of Florida as a venue attracted some
>> >>> questions. We asked Fred Posner of Posner | Palner about the clinical
>> >>> background informing this choice of replication study cohort:
>> >>> 
>> >>> "Florida is a good place to find eventual consistency failures; the
>> >>> open climate and reluctance to accept traditional data integrity
>> >>> science would have sealed the deal, but when people started to drink
>> >>> bleach here, I saw an opportunity."
>> >>> 
>> >>> Evariste and Posner | Palner are aiming for a US Food & Drug
>> >>> Administration EUA (Emergency Use Authorisation) for DMQ replication
>> >>> as a prophylactic data redundancy and failover measure to ward off
>> >>> the development of moderate to severe viral Sonus Haemorrhagic Fever 
>> >>> symptoms.
>> >>> 
>> >>> Phase II studies have painted a promising a picture of the DMQ
>> >>> architecture's ability to reduce moderate to severe symptoms and
>> >>> associated 28-day mortality by more than 90%, albeit over a small
>> >>> sample size and in enterprise patients with known pre-existing
>> >>> comorbidities such as Session Border Controller and BroadSoft
>> >>> Multi-System Inflammatory Syndrome.  Phase III trials seek to bolster
>> >>> quantums of broader efficacy, including efficacy for localised 
>> >>> outbreaks of small to medium business softswitch.
>> >>> 
>> >>> Of the control group, Balashov said, "They will receive a standard
>> >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
>> >>> confirmation messages. We proudly developed this approach in early
>> >>> 2020 in consultation with the highest levels of the Trump
>> >>> presidential administration; it is called TENP, or 'The Emperor's New
>> >>> Potion.' It is a successor to that administration's previous approved 
>> >>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
>> >>> 
>> >>> Despite speculative autism and packet fragmentation claims by Florida
>> >>> Governor Ron DeSantis, Balashov was quick to provide reassurance
>> >>> about side effects from DMQ in the Phase III trial.
>> >>> 
>> >>> "The incidence of severe allergies to plain-text UDP was within
>> >>> standard deviation over the mean for all insecure replication, and
>> >>> there's support for other transports on the way. Anyway, we have a
>> >>> robust adverse effects reporting system in our issue tracker and
>> >>> solid surveillance. Don't let partisan politics dissuade you from 
>> >>> allowing request lines with the KDMQ method."
>> >>> 
>> >>> Other industry sources have reported that DMQ is not the only
>> >>> replication investigation undertaken by Evariste and Posner | Palner,
>> >>> although it is the only prophylactic suitable for the early infection
>> >>> development and inflammatory phases of a broad class of SBC-complex
>> >>> syndromes typically afflicting service providers. A recent IETF
>> >>> preprint by the same authors has shown high-quality preliminary data
>> >>> suggesting statistically significant improvement in morbidity
>> >>> outcomes from Perimeta and Nokia via a later-stage therapeutic 
>> >>> intervention with a monoclonal, monorepo Github cocktail administered 
>> >>> intravenously.
>> >>> 
>> >>> 
>> >>> --
>> >>> Alex Balashov | Principal | Evariste Systems LLC
>> >>> 
>> >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
>> >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
>> >>> _______________________________________________
>> >>> VoiceOps mailing list
>> >>> VoiceOps at voiceops.org
>> >>> https://puck.nether.net/mailman/listinfo/voiceops
>> > _______________________________________________
>> > VoiceOps mailing list
>> > VoiceOps at voiceops.org
>> > https://puck.nether.net/mailman/listinfo/voiceops
>> > 
>> > ----------------------------------------------------------------------
>> > This message and any attachments are intended only for the use of the
>> > addressee and may contain information that is privileged and
>> > confidential. If the reader of the message is not the intended
>> > recipient or an authorized representative of the intended recipient,
>> > you are hereby notified that any dissemination of this communication
>> > is strictly prohibited. If you have received this communication in
>> > error, notify the sender immediately by return email and delete the
>> > message and any attachments from your system.
>> > _______________________________________________
>> > VoiceOps mailing list
>> > VoiceOps at voiceops.org
>> > https://puck.nether.net/mailman/listinfo/voiceops
>> _______________________________________________
>> VoiceOps mailing list
>> VoiceOps at voiceops.org
>> https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://puck.nether.net/pipermail/voiceops/attachments/20210401/938ea25d/attachment.htm>